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In this study, the phenotype of psoriatic keratinocytes and ﬁbroblasts in reconstructed skin models was compared
to those constructed from normal cells. Characterization of this model by immunohistochemistry showed that
classical markers of keratinocyte differentiation exhibited similar patterns of distribution in the psoriatic models to
those derived from normal cells and generally reﬂected in vivo observations. Some crucial differences, however,
were observed between normal and psoriatic models when pro-inﬂammatory gene expression and keratinocyte
proliferation were investigated. Notably, the chemokine receptor CXCR2 was overexpressed in the psoriatic mod-
els, and, moreover, was localized to the granular layer of keratinocytes as seen in psoriasis in vivo. Pro-inﬂam-
matory genes (tumor necrosis factor alpha [TNF-a], interferon gamma [IFN-c], and interleukin 8 [IL-8]) were
expressed at high levels in the psoriatic models, but were only minimally expressed in the normal models. Models
derived from uninvolved psoriatic skin showed the same gene expression proﬁle as those derived from involved
skin along with an increased proliferation rate when compared to normal models. These results suggest that
psoriatic individuals possess an inherent predisposition to develop the disease phenotype even in the absence of T
cells. This study represents a comprehensive characterization of psoriatic human skin reconstructed in vitro, and
demonstrates the potential of this model as a valuable tool in drug discovery.
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Psoriasis is an inflammatory skin disorder, suggested to be
triggered or exacerbated by a number of genetic, environ-
mental, or immunological factors. The disease is charac-
terized by hyperproliferation of keratinocytes; abnormal
epidermal differentiation; and infiltration of inflammatory
cells (Stern, 1997). These include Th1 cells that have been
activated by dermal dendrocytes and neutrophils in a dense
focal accumulation in the upper epidermis (Gillitzer et al,
1996). Pro-inflammatory cytokines and chemokines, re-
leased from multiple cell types, interact in a complex
pattern to influence the pathological events leading to the
development of the psoriatic plaque (Prens et al, 1990;
Bata-Csorgo et al, 1995; Gillitzer et al, 1996; Mizutani et al,
1997; Fukuoka et al, 1998).
Research into psoriasis, and the subsequent develop-
ment of therapeutic strategies, has been hindered by
the absence of relevant models of the disease. The severe
combined immunodeficiency (SCID) mouse has been used
as an in vivo model, in which psoriatic plaques transplanted
onto the animal have maintained the clinical, histological,
and immunological characteristics of the disease for suffi-
cient time to allow the efficacy of potential therapeutic
compounds to be tested (Raychaudhuri et al, 2001). Animal
models, however, can prove unsatisfactory, as allogeneic
differences can cause artifactual immune responses, fur-
nished by the xenograph, which may differ from that of
psoriasis. Various attempts to model aspects of the disease
in vitro have been reported, using both monolayer and
stratified keratinocyte cultures (Saiag et al, 1985; Chapman
et al, 1990; Mils et al, 1994; Van Ruissen et al, 1996a, b; Pol
et al, 2002). Some previous studies have demonstrated
the importance of crosstalk between the keratinocyte and
the fibroblast in modeling the disease in vitro (Krueger
and Jorgensen, 1990; Konstantinova et al, 1996; Krueger
and Jorgensen, 1997). An organotypic culture system that
accurately models the diseased tissue architecture, with the
added potential of the introduction of multiple cell types,
however, has not been previously characterized. A defined,
serum-free environment is particularly advantageous, by
allowing the precise control of experimental conditions.
The studies described here were carried out to compare
proliferation and gene expression in skin models derived
from normal cells with those derived from involved and un-
involved psoriatic cells, with the aim of developing a robust
in vitro model of psoriasis that could be used as a valuable
tool in basic research and drug discovery. Genes investi-
gated were relevant to keratinocyte proliferation (Ki67),
hyperproliferation (cytokeratin 16), and differentiation (cyto-
keratin 10, involucrin, and filaggrin) or have previously been
implicated in the pathophysiology of psoriasis, i.e., primary
cytokines (TNF-a, IFN-g, IL-6) and the chemokine receptors
CXCR1 and CXCR2, and their ligands IL-8 and GRO-a.
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Results
Patient demographics All of the 12 patients who were
biopsied had chronic plaque psoriasis. Their mean age was
50 y (range 34–75 y), nine were female, mean duration of
psoriasis was 19 y (3–40 y) and mean psoriasis area and
severity index (PASI) at biopsy was 9.7 (2.6–22.2).
Reconstruction of normal and psoriatic skin in vitro
Skin models derived from normal, involved psoriatic, and
uninvolved psoriatic cells models were grown from keratin-
ocyte and fibroblast cultures with o0.1% contaminating
CD3 or CD45 positive cells as determined by immunocyto-
chemistry. All displayed excellent epidermal morphology
using the defined, serum-free culture system (Fig 1). A
compact basal layer gave rise to larger spinous layer of
differentiating cells. Several flattened cell layers formed the
granular layer, containing keratohyalin granules, beneath
the stratum corneum. The stratum corneum was in most
cases anuclear; however, occasionally models of all types
displayed some parakeratosis. All of the major morpholog-
ical layers were evident by day 7; continuation of the culture
period to day 21 resulted in a more highly differentiated
epidermis, with a progressively thicker cornified layer. Der-
mal fibroblasts in the collagen gel aligned horizontally with
the basement membrane. No obvious differences in epi-
dermal thickness were observed between normal and
psoriatic models. Ki67 staining present in the basal and
lower suprabasal layers of the models, however, showed a
significant increase in proliferation in the psoriatic models
compared to the normal controls over 7, 14, and 21 d
po0.02, n¼ 4 (Fig 2). No difference in proliferation was ob-
served between the involved and uninvolved models. Figure
2 also shows that the proliferation rates were similar
between 7 and 14 d but were significantly lower after 21 d
in both normal and psoriatic models.
Patterns of gene expression (Fig 3) in psoriatic unin-
volved cultures were the same as those for involved cultures
for all genes investigated (uninvolved data not shown).
Cytokeratin 16 was not detected in normal skin biopsies
(in vivo) but was strongly expressed in suprabasal psoriatic
keratinocytes in skin models from normal, psoriatic–
involved, and psoriatic-uninvolved sources. Also indicative
of the hyperproliferative phenotype was the precocious ex-
pression of involucrin, which was present in all suprabasal
keratinocytes in all in vitro skin models and in psoriasis
in vivo, although localized to the upper spinous and granular
layers in normal skin. In contrast, the expression patterns of
cytokeratin 10 and filaggrin were not altered in psoriasis
in vivo and again this was reflected in vitro: cytokeratin 10
was consistently expressed in all suprabasal keratinocyte
layers, whereas filaggrin was localized to the granular layer.
Characterization of the psoriatic phenotype in vitro
Primary cytokines No expression of TNF-a, IFN-g or IL-6
was observed in normal skin, either in vivo or in vitro (Fig 4).
TNF-a and IFN-g were localized to the granular layer ker-
atinocytes in psoriatic lesions in vivo, particularly around
microabcesses, with weak expression also in the spinous
layer. Some staining in mononuclear cells was observed
around the dermal papillae. The psoriatic skin models
showed strong staining for both TNF-a and IFN-g through-
out the keratinocyte layers, with intense staining in the
granular layer. IL-6, in contrast, showed general staining
throughout the basal and suprabasal keratinocyte layers of
both normal and psoriatic skin, in vivo and in vitro. Occa-
sional keratinocytes displayed intense cytoplasmic staining,
Figure 1
Reconstruction of human skin in vitro in a
fully defined, serum-free environment. Ker-
atinocytes were seeded onto collagen gels
containing dermal fibroblasts and grown to a
confluent monolayer. Subsequent exposure to
the air–liquid interface for 21 d resulted in the
formation of a fully differentiated epidermis.
Figure shows typical morphology of normal,
psoriatic involved and psoriatic uninvolved
models after 7, 14, and 21 d of air exposure.
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particularly in the in vitro models. The lowest level was seen
in normal skin in vivo. Fibroblasts showed strong staining,
particularly in psoriatic in vitro skin.
Chemokines and chemokine receptors Expression of the
interleukin-8 receptors, CXCR1 and CXCR2, are shown in
Fig 5. There was absence of CXCR1 in keratinocytes both
in vivo and in vitro. This receptor, however, was clearly ex-
pressed in infiltrating inflammatory cells in vivo. Figure 5
shows some striking differences in CXCR2 expression be-
tween normal and psoriatic skin, both in vivo and in vitro.
CXCR2 was not detectable in normal in vivo skin and in the
normal in vitro models. In contrast, in psoriatic skin, CXCR2
was expressed in the suprabasal keratinocytes, with a con-
centrated band of expression in the terminally differentiating
granular layer. This pattern of distribution was precisely re-
produced in the in vitro model of psoriasis, regardless of
whether the cells were derived from the involved or the
uninvolved body site. (This was evident by day 7 at the air–
liquid interface—data not shown). The expression profile of
CXCR2 was confirmed at the mRNA level by RT-PCR of
mRNA extracted from skin models derived from three
psoriatic patients and three controls. Figure 6 shows a rep-
resentative result of the RT-PCR analysis of CXCR2 ex-
pression compared to the housekeeping gene GAPDH
using mRNA extracted from in vitro models prepared from
Figure 2
Proliferation of keratinocytes in normal and psoriatic models of
human skin. Figure shows the mean number of Ki67 positive cells in
normal (open columns), involved (black filled columns) and uninvolved
(gray filled columns) psoriatic models cultured for 7, 14, and 21 d.
Models derived from involved or uninvolved psoriatic skin showed
higher rates of proliferation compared to normal models po0.02 n¼ 4.
Proliferation rates were similar after 7 and 14 d culture but were sig-
nificantly reduced after 21 d for all cases tested po0.002. Error bars
representþSD.
Figure 3
Markers of keratinocyte proliferation and
differentiation in normal and psoriatic
models of human skin. Figure shows ex-
pression of Ki67, cytokeratin 16, cytokeratin
10, involucrin and filaggrin in organotypic
models of normal and psoriatic (involved) hu-
man skin after 21 d of air exposure. Models
derived from uninvolved psoriatic skin showed
identical patterns of gene expression to those
derived from involved skin (data not shown). In
vivo normal and psoriatic (involved) skin is
shown for comparison.
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one case of psoriasis, one control skin, and in vivo tissues
from the same cases.
Immunohistochemical analysis of IL-8 and GRO-a, the
major ligands of CXCR2, is shown in Fig 5. In agreement
with in vivo observations, IL-8 expression was minimal
in the normal in vitro models. The low levels of IL-8 expres-
sion were in line with expectations, given the hyperprolif-
erative in vitro environment. In contrast, both involved and
uninvolved psoriatic models expressed high concentrations
of IL-8 throughout the viable keratinocyte layers. This pat-
tern of distribution agreed with that observed in psoriasis in
vivo. In all cases, the stratum corneum was negative for IL-8.
GRO-a expression in normal epidermis in vivo was neg-
ligible, and this was reflected in the normal in vitro models.
Figure 4
Expression of primary cytokines in nor-
mal and psoriatic human skin models.
Figure shows expression of TNF-a, IFN-g,
and IL-6 in models of normal and involved
psoriatic human skin after 21 d of air ex-
posure. Models derived from uninvolved
psoriatic skin showed identical patterns of
gene expression to those derived from in-
volved skin. In vivo normal and involved
psoriatic skin are also shown for compar-
ison.
Figure 5
Expression of CXCR1, CXCR2, and their
major ligands in normal and psoriatic hu-
man skin models. The figure shows expres-
sion of CXCR1, CXCR2, IL-8, and GROa in
normal and involved psoriatic human skin
and in vitro models after 21 d of air exposure.
Models derived from uninvolved psoriatic
skin showed identical patterns of gene ex-
pression to those derived from involved skin
(not shown). In vivo normal and involved
psoriatic skin are also shown for comparison.
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Like IL-8, GRO-a was highly expressed in psoriasis in vivo
and in involved and uninvolved models in vitro (Fig 5). In
contrast to IL-8, however, a change in the pattern of dis-
tribution of GRO-a was noted during the culture period. At
days 7 and 14, the chemokine was strongly expressed in all
of the viable keratinocyte layers (data not shown). By day
21, expression became concentrated into a strong band in
the granular keratinocytes, with much weaker staining in the
other layers. This pattern of expression was also observed
in some in vivo psoriatic skin samples. In all cases, the
stratum corneum remained negative, both in vivo and
in vitro.
Expression of IL-8 and GRO-a in vitro was further inves-
tigated by quantitation of the chemokines in conditioned cul-
ture media using multiplex ELISA technology (Fig 7).
Inter-donor variation was observed in both normal and
psoriatic models. Examination of the data from individual
donors, however, revealed that those producing more IL-8
also produced more GRO-a (individual data not shown). All
donors showed a clear, statistically significant reduction in
IL-8 production over the 21-d culture period, with the most
marked reductions occurring before Day 7. This phenom-
enon was also observed in terms of GRO-a levels produced
by the psoriatic models. In contrast, GRO-a levels remained
fairly constant during the differentiation phase in the normal
models, with no significant difference between time points.
At all times, conditioned medium from skin models derived
from psoriatic donors contained higher levels of both IL-8
and GRO-a in involved samples relative to the uninvolved.
Surprisingly, in the case of GRO-a it was also observed that
the normal models produced considerably (up to 5–10-fold)
higher quantitative levels of GRO-a than any of the psoriatic
models.
Discussion
This study represents a comprehensive characterization of
psoriatic human skin reconstructed in vitro, and demon-
strates the potential of this model as a valuable tool in drug
discovery. The reconstruction of skin from multiple psoriatic
donors demonstrated a robust culture system, which al-
lowed many genes of relevance to the disease to be ex-
pressed in a fully defined, serum-free environment. The
optimized culture conditions allowed important differences
between normal and psoriatic cells to be retained in vitro
through at least two subcultures.
Skin undergoing reconstruction in the in vitro environ-
ment is, by nature, hyperproliferative, and therefore, dis-
plays some phenotypic features in common with in vivo
psoriasis (Boelsma et al, 2000; Gibbs et al, 2000), as clearly
demonstrated in Fig 3. These results suggest that certain
characteristics of psoriasis, relating to the hyperproliferative
keratinocyte and its subsequent abnormal differentiation,
may be open to study using in vitro models. It should be
noted that none of these cultures, regardless of tissue
source, show the psoriasiform morphology and regenera-
tive maturation features of lesional skin (Fig 1). The involved
and uninvolved psoriatic models, however, showed higher
rates of proliferation compared to the normal models (Fig 2).
This observation is consistent with the idea that proliferation
rates are modified in vitro, but still retain in vivo differences
between the cell populations. Proliferation, therefore, de-
pends upon the inclusion of growth-promoting agents such
as human epidermal growth factor (hEGF) in the medium
and the intrinsic production of these agents such as IL-8
and Gro-a by the keratinocytes and fibroblasts in the model.
The minimal media used in these studies have only low
levels of recombinant hEGF (0.1 ng per mL) and much
higher levels (1–2 ng per mL) are required for increased
suprabasal keratinocyte proliferation (Maas-Szabowski
et al, 2003). Previous research has shown that the epithe-
lial–mesenchymal signaling is altered in psoriasis generating
increased hyperplasia of the epidermis even in uninvolved
skin (Ting et al, 2000; Chen et al, 2001). This increased
sensitivity to proliferation has been shown to be mediated
by dermal fibroblasts from psoriatic donors which can
change the proliferation rate of keratinocytes from normal
skin (Saiag et al, 1985; Krueger and Jorgensen, 1997).
The release of primary cytokines plays a key role in the
initiation of psoriasis. TNF-a is produced by both dermal
dendrocytes and epidermal keratinocytes (Nickoloff et al,
1991) and induces the release of cytokines such as IL-8
(Barker et al, 1990; Giustizieri et al, 2001), which subse-
quently act as important keratinocyte mitogens in the hyper-
proliferative response. IFN-g, produced by T cells and
keratinocytes, also stimulates keratinocyte growth, both
directly (Bata-Csorgo et al, 1995) and through stimulation
of IL-1b production (Wei et al, 1999). Downregulation of
epidermal TNF-a and IFN-g levels has been shown to cor-
relate with clinical improvement of psoriasis (Reich et al,
Figure6
Representative RT-PCR analysis of in vivo tissues
and in vitro models showing CXCR2 and GAPDH
mRNA expression. Gel electrophoresis of RT-PCR
reactions using mRNA extracted from the following
samples: in vivo skin: normal (1 and 2), psoriatic in-
volved (3 and 4); in vitro skin models: normal (5 and 6),
uninvolved (7 and 8), involved (9 and 10) after 14 d
culture. Odd tracks show PCR reactions without a re-
verse transcriptase step () even tracks show com-
plete RT-PCR reactions (þ ). PCR cycles were limited
for CXCR2 to observe different levels of expression.
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2001). There is also some evidence that primary cytokines
such as TNF-a and IFN-g are expressed by keratinocytes in
psoriasis (Livden et al, 1989; Kristensen et al, 1993), and
this was supported by the results of our studies. The prin-
cipal source of these pro-inflammatory cytokines, however,
is known to be activated T cells in the lesion. Keratinocyte-
derived TNF-a and IFN-g may exaggerate the psoriatic
phenotype by extending the T cell-mediated signal (Wei
et al, 1999).
IL-6 has also previously been implicated in the patho-
genesis of psoriasis (Prens et al, 1990; Ameglio et al, 1997),
with potentially important roles in both inflammation and
keratinocyte mitogenesis (Grossman et al, 1989). Studies by
Oyama et al (1998) suggested that IL-6 might potentiate
keratinocyte growth partly through the induction of the EGF
receptor. Our studies demonstrated that the hyperprolifer-
ative in vitro environment stimulated IL-6 expression in both
normal and psoriatic keratinocytes during the first 7 d of
growth as also shown by Goretsky et al (1996) and Fayyazi
et al (1999). It is possible that the fibroblasts present in
these models also contribute to the total levels of this cyto-
kine. Future studies should investigate the expression and
role of IL-1a and IL-1b in the psoriatic models, since recent
studies have shown that this is a dominant pro-inflamma-
tory cytokine (Steude et al, 2002).
The CXCR2/IL-8/GRO-a pathway is considered to play
an important role in wound healing (Devalaraja et al, 2000)
and the pathogenesis of psoriasis (Jiang et al, 2001; Reich
et al, 2001). IL-8 and GRO-a are CXC chemokines that are
barely detectable in normal epidermis (Gillitzer et al, 1996),
but are upregulated in psoriasis (Anttila et al, 1992). The
results of our studies confirmed these findings both in vivo
and in vitro although GRO-a was also expressed in the
normal in vitro models. In addition, IL-8 has been shown to
be a potent stimulator of epidermal cell proliferation (Tuschil
et al, 1992) as well as angiogenesis and keratinocyte mi-
gration (Koch et al, 1992), both important aspects of psoria-
tic pathology. Steude et al (2002) have recently shown that
exogenous IL-8 (100 ng per mL) added to the culture me-
dium stimulate normal keratinocyte growth in organotypic
cultures of human skin. Our studies have shown that en-
dogenous secreted levels of IL-8 of 70 ng per mL are high-
est at the onset of stratification in organotypic cultures, but
rapidly decline as a differentiated epidermis forms to 1–2 ng
per mL after 21 d. GRO-a levels, however, remained high in
the media of normal models throughout the culture period
suggesting that the turnover of this ligand was much lower
in the normal model.
The receptor CXCR2 is overexpressed in the differenti-
ated keratinocytes of the psoriatic plaque (Beljaards et al,
1997; Kulke et al, 1998) and in response to cutaneous injury
(Nanney et al, 1995; Devalaraja et al, 2000) but is barely
detectable in normal epidermis. Steude et al (2002) also
demonstrated that CXCR2 is the receptor responsible for
mediating the keratinocyte growth response to IL-8 and
Figure7
ELISA detection of chemokine levels in conditioned culture media
from skin models using luminex beads. Each panel shows the mean
level of each chemokine detected in the culture medium for media
sampled at 0, 2, 7, 14, and 21 days. Panels show the levels of IL-8 (A),
IL-6 (B) and GRO-a (C) for normal skin models (open columns) (n¼4)
and psoriatic skin models (n¼3) Black filled columns show results of
models derived from involved skin and gray filled columns from unin-
volved skin. Error bars represent mean  SEM.
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GRO-a in vitro. Although we were able to detect high levels
of IL-8 and GRO-a, and CXCR2 in the psoriatic models, this
was not accompanied by the development of a psoriasiform
morphology due to extended hyperproliferation of keratin-
ocytes. The IL-8 levels that were released into the culture
medium after 7 d in our studies were significantly lower than
those used by Steude et al (2002) to promote further ker-
atinocyte growth. Therefore, the production and release of
these ligands may require other T cell-mediated signals
to extend keratinocyte growth in the psoriatic model. The
immunohistochemistry data have shown that IL-8 and
GRO-a were both expressed and retained in the psoriatic
models in agreement with in vivo staining, but in the case of
the normal models, the majority was secreted into the me-
dium. The source of these ligands is likely to be the ker-
atinocytes but they could also come from the fibroblasts as
they have been shown to produce higher levels of Il-8
(Konstantinova et al, 1996) and IL-6 (Grossman et al, 1989)
in psoriasis. Thus release of these chemokines and the
overexpression of the CXCR2 receptor may be key regu-
latory factors influencing the growth of keratinocytes in
psoriasis. Future work will investigate the importance of
CXCR2 signaling in psoriatic models by the use of blocking
antibodies and gene transfer experiments in psoriatic and
normal models.
The current studies have shown that psoriatic skin re-
constructed in vitro partially displays the psoriatic phe-
notype. This includes an abnormal differentiated phenotype
typical of a hyperproliferative environment; expression
of pro-inflammatory cytokines; and the presence of the
chemokine receptor CXCR2 and its ligands IL-8 and GRO-
a. The model supports the hypothesis that the keratinocytes
and fibroblasts of individuals susceptible to psoriasis pos-
sess inherent differences from normal individuals, which
contribute to the disease phenotype. The model developed
in these studies could provide a starting point to investigate
the mechanisms of abnormal keratinocyte growth and gene
expression in psoriasis, as well as acting as a valuable tool
in drug discovery. Future studies on blocking receptor
signaling and incorporating other cell types, such as T cells,
could provide important clues regarding the interaction be-
tween cell types in psoriasis.
Materials and Methods
Patient details Patients with active chronic plaque psoriasis
(n¼ 12) were recruited to the study from the dermatology outpa-
tient’s clinic at Leicester Royal Infirmary (age, sex, duration of dis-
ease, severity PASI). All patients gave informed written consent.
During 1 mo prior to biopsy, they had received no therapy for the
psoriasis. Six millimeter punch biopsies were taken under local
anesthetic (2% lignocaine with no added adrenaline) from chronic
plaques, which had been present for 1–4 wk. Biopsies were also
taken from uninvolved skin approximately 50 mm from the active
lesion. Immediately after excision, biopsies were transported to the
laboratory in Leibovitz L-15 medium and processed for skin re-
construction. Alternatively, excision biopsies were mounted in
optimal cutting temperature of freezing medium (OCT) on cork,
frozen in isopentane precooled in liquid nitrogen, and stored in
liquid nitrogen vapor until further processing for immunohisto-
chemistry. Normal skin from non-psoriatic patients (n¼ 12) was
obtained, following informed patient consent, from reduction ma-
mmoplasty. The subjects were Caucasian females aged between
23 and 62. This study was conducted in agreement with the Dec-
laration of Helsinki and performed under the guidelines of the local
medical ethics committee for University Hospitals of Leicester NHS
Trust, England, with written consent of the patients.
Isolation and culture of epidermal keratinocytes and dermal
ﬁbroblasts from human skin Following overnight incubation at
41C, in 10 U per mL protease in Leibovitz L-15 medium (both from
Sigma-Aldrich, Poole, UK), the epidermis was peeled away from
the dermis. The epidermis was incubated in 0.05% trypsin/0.02%
(wt/vol) EDTA (Life Technologies, Paisley, UK) for 20 min at 371C.
Trypsin activity was neutralized with 10% fetal calf serum (FCS) in
phosphate-buffered saline (PBS) (Life Technologies), the cells were
pelleted by centrifugation and resuspended in Clonetics Keratin-
ocyte Growth Medium (KGM) (Biowhittaker, UK) at 0.06 mM cal-
cium. Keratinocytes were seeded into culture in KGM on a coating
of fibronectin and collagen I (FNC, from Biological Research Fac-
ulty and Facility, Ijamsville, Maryland). Following a 4-h attachment
period at 371C/5% (vol/vol) CO2, the medium was replaced to
remove any non-viable or unattached cells. The dermis was
incubated in 0.25% (wt/vol) collagenase A (Roche, Mannheim,
Germany) in Dulbecco’s Modified Eagles Medium (Life Technolo-
gies) with 10% (vol/vol) FCS for 24 h at 371C/5% (vol/vol) CO2.
Fibroblasts were pelleted by centrifugation, resuspended and
seeded into culture in DMEM with 10% (vol/vol) FCS. All cultures
were incubated at 371C/5% (vol/vol) CO2, and re-fed with fresh
medium every 2–3 d. The purity of the cell populations was con-
firmed by immunocytochemistry using primary antibodies to CD3,
CD68, and CD45 to detect contaminating T cells, macrophages or
leucocytes, and anti-cytokeratin and anti-fibroblast antigen 1 to
confirm the presence of keratinocytes and fibroblasts. Keratin-
ocytes were used to generate organotypic cultures at passage
numbers 1 and 2, and fibroblasts cultures were used up to pas-
sage 3.
Generation of organotypic cultures The culture system was a
modified version of that described by Stark et al (1999). All exper-
iments generated at least triplicate models from each patient
source. Fibroblasts were harvested from monolayer culture using
0.05% trypsin/0.02% (wt/vol) EDTA. The cells were pelleted by
centrifugation and resuspended in FCS at a concentration of
2  106 per mL. Collagen gels were prepared by mixing eight vol-
umes of rat tail collagen I (Pharmingen, San Diego, California) with
one volume of 10  Hanks Balanced Salt Solution (HBSS) (Life
Technologies), neutralizing the pH with 0.2 M sodium hydroxide,
and adding one volume of the resuspended fibroblasts (passage 1)
in FCS. This gave a final fibroblast concentration of 2  105 per
mL. The gel mixture was added to polycarbonate membrane filter
inserts (Becton Dickinson) (2.5 mL per insert) in six-well culture
plates. After an initial incubation period of 1 h at 371C/5% (vol/vol)
CO2 to allow the gels to set, 2 mL DMEM was added to the surface
of the gels and a further 2 mL to the culture dish. The gels were
incubated for 3 d to allow the onset of deposition of extracellular
matrix proteins. After this time, keratinocyte medium was used
throughout the culture period. The composition of the medium was
modified to give a fully defined system in the absence of bovine
pituitary extract. Clonetics KGM was purchased as a calcium-free
‘‘bullet kit’’ and supplemented with the following: EGF, insulin, hy-
drocortisone, transferrin, and epinephrine were added from the
bullet kit to give final concentrations as defined by the manufac-
turer. Gentamicin (5 mg per mL) (Life Technologies), L-ascorbic acid
(50 mg per mL) (Sigma-Aldrich), bovine serum albumin (0.1% w/v)
(Sigma-Aldrich), and calcium chloride (0.06 or 1.8 mM as specified)
(BDH, Poole, UK) were also added. The modified medium was
denoted as Supplemented Keratinocyte Growth Medium (SKGM).
Keratinocytes were harvested from monolayer culture using a
20 min pre-incubation in 0.05% (wt/vol) EDTA in PBS to loosen the
intercellular junctions, followed by a 1 min incubation in 0.05%
trypsin/0.02% EDTA (wt/vol). This method minimized exposure to
trypsin, which can be particularly damaging to keratinocytes. The
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keratinocytes were seeded onto the surface of the gels, using
1  106 cells per gel, in 350 mL SKGM at 0.06 mM calcium. Ker-
atinocytes were always derived from the same donor as the fib-
roblasts; both normal and psoriatic cells seeded onto gels at
passage 2. After an initial attachment period of 30 min, the medium
was made up to a total of 2 mL on the surface of the gel and 2 mL
in the culture dish. When a confluent monolayer had formed (usu-
ally after 24 h), the calcium concentration was raised to 1.8 mM to
stimulate the onset of differentiation. After a further 48 h, the cul-
tures were exposed to the air–liquid interface by adjusting the level
of the medium: 2 mL was applied to the culture dish only, in order
to feed the skin models from the basal side. The models were
maintained at the air–liquid interface for up to 21 days, and were
re-fed with 2 mL fresh medium every 2–3 d. Conditioned medium
was collected for analysis of IL-8, GRO-a, and IL-6 levels by ELISA.
Skin models were harvested at specified time points, fixed in buff-
ered formalin and processed in paraffin wax for immunohisto-
chemistry.
ELISA A capture sandwich immunoassay was carried out using
LabMAP Capture Microspheres (Luminex Corporation, Austin,
Texas). Capture antibody beads were incubated with samples,
prior to addition of LabMAP biotin-conjugated detection antibody
for cytokine and the subsequent addition of streptavidin. Briefly,
LabMAP Cytokine Capture Microspheres (GRO-a, IL-6 and IL-8,
Luminex, Austin, Texas) were diluted 1:25 in PBSBN (PBS pH 7.4,
1% BSA-fraction V and 0.05% sodium azide) and added together
in a multiplex in a 96-well plate (1.2 mm pore filter plate, Millipore;
50 mL total volume per well). Standard curves were prepared using
human cytokines (GRO-a, IL-6 and IL-8, Pharmingen, San Diego,
California) suitably diluted in PBSBN. Aliquots of the human cyto-
kine standard curves (50 mL total volume) were added to the cap-
ture antibody beads in columns 1 and 12 of the plate. Biological
samples were added to the remaining columns of the plate (50 mL
total volume), mixed using a plate shaker and incubated in the dark
at room temperature for 1 h. After washing twice with PBSBN
(100 mL per wash), LabMAP biotin-conjugated cytokine detection
antibodies (IL-6, IL-8 and GRO-a Luminex) were diluted 1:25 and
added to the corresponding wells in the 96-well plate (50 mL total
volume per well). In addition, PBSBN (50 mL) was added to each
well. The plate was shaken and then incubated in the dark at room
temperature for a further 1 h. After washing twice with PBSBN
(100 mL per wash), streptavidin/PE (10 mg per mL, 50 mL; Molecular
Probes, Leiden, Holland) and PBSBN (50 mL) was then added to
Table I. Antibodies used immunohistochemical staining of skin models
Antibody Isotype Supplier Catalogue no.
Concentration
(lg per mL) dilution Antigen retrieval
CXCR1 IgGb2 Pharmingen 35781D 1 Microwave
CXCR2 IgG1 Biosource, Camarillo,
California
AHR1532X 0.5 Microwave
Ki-67 IgG1 Dako M7187 0.35 Microwave
CK10 IgG Dako M7002 0.1 Microwave
CK16 IgG1 Novocastra, Newcastle
upon Tyne, UK
NCL-CK16 1:40 Microwave
Involucrin IgG1 Novocastra NCL-INV 1:5000 Microwave
Filaggrin IgG1 Biogenesis, Poole, UK 4480-9004 1:1000 Microwave
MNF116 IgG1 Dako M0821 0.02 Microwave
Collagen IV IgG1 Dako M0785 2 Proteinase K
Collagen VII IgG1 Chemicon MAB2500 5 Proteinase K
Laminin V IgG1 Chemicon MAB19562 5 Proteinase K
IL-8 IgG1 R&D Systems,
Abingdon, UK
MAB208 1.25 None
GROa IgG2b R&D Systems MAB275 1.25 None
IFN-g IgG2a R&D Systems MAB285 2.5 None
TNF-a IgG1 R&D Systems MAB610 5 None
IL-1a IgG2a R&D Systems MAB200 5 None
IL-6 IgG1 R&D Systems MAB206 10 Microwave
IL-6R IgG1 R&D Systems MAB227 10 None
CD45 IgG1 Dako M0701 0.45 Microwave
CD3 Poly Dako A0452 1:400 Microwave
CD68 IgG3 Dako M0876 0.625 Microwave
Fibroblast antigen (Ab-1) IgG1 Oncogene, Bostan,
Massachusetts
CP28 10 Frozen section
or cytospin
Control IgG1 Dako X0931 1–10 –
Control IgG2a Dako X0943 1–10 –
Control IgG2b Dako X0944 1–10 –
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the 96-well plate and incubated in the dark at room temperature for
30 min. After two further washes with 100 mL PBSBN and one wash
with 100 mL PBS, 100 mL PBS was added to each well before
measurement. Samples (50 mL) were assayed for cytokine levels
using the Luminex100 96-well plate reader, counting 200 events
per bead.
Immunohistochemistry In vivo skin and in vitro skin models were
fixed in 10% (v/v) buffered formalin prior to processing in paraffin
wax for immunohistochemistry. Paraffin sections were cut onto
aminopropyltriethoxysilane-coated slides and dried overnight at
371C. Immunohistochemical staining to characterize the skin mod-
els was carried out using antibodies listed in Table I at the stated
dilutions using the streptavidin–biotin complex (ABC) method. Ap-
propriate antigen retrieval steps were applied to optimize staining.
Briefly, the sections were treated for antigen retrieval, if appropri-
ate, after deparaffinization either for 2.5 min at 700 W  2 in citrate
buffer pH 6.0 in a suitable microwave oven or digested in protein-
ase K (5 mg per mL) for 1 h at 371C. The sections were equilibrated
in Tris-buffered saline pH 7.6 (TBS) prior to blocking in 20% normal
rabbit serum (NRS) in TBS for 10 min, and then incubated with the
primary antibody diluted in 20% NRS for 18 h at 41C in a humidity
chamber. After washing in TBS, sections were incubated in bio-
tinylated rabbit anti-mouse F(ab)2 (Dakopatts, Glostrup, Denmark)
diluted 1:400 in 20% NRS for 30 min, followed by 30 min incu-
bation in pre-alkaline phosphatase conjugated ABC (Dako). Fol-
lowing the final washes in TBS, sections were detected with Fast
Red TR salt (Sigma F-2768) and Naphthol AS-BI phosphate (Sigma
N-2250) in a Veronal acetate buffer (VAB). The sections were then
counterstained in hematoxylin and mounted using an aqueous
mounting medium. For each case, a negative control with omission
of the primary antibody was included. Two observers (A.K.G.,
J.H.P.) scored the immunostaining. For proliferation studies, Ki67
positive stained cells were counted for each model from 20 fields
using an objective with magnification of  40. Four cases of pso-
riasis with involved and uninvolved models and four normal mod-
els, each in duplicate, were analyzed for proliferation.
RT-PCR mRNA was extracted from tissue sections of normal and
psoriatic skin models using oligo d(T)-labeled paramagnetic beads
according to the manufacturers instructions (Dynal, UK). The sec-
tions were immediately dropped into 100 mL of lysis/binding buffer
(100 mM Tris-HCl, pH 8.0; 500 mM LiCl; 10 mM EDTA, pH 8.0; 1%
wt/vol sodium dodecyl sulfate; 5 mM dithiothreitol). mRNA was
extracted and processed using oligo-dT-linked Dynabeads (Dynal,
Bromborough, UK), as described previously by Bicknell et al
(1996). Reverse transcription reactions were carried out at 421C for
1 h using Expand-RT (Boehringer Mannheim) in accordance with
the manufacturer’s instructions. In a total volume of 25 mL, reac-
tions contained 5 mL Expand RT buffer, 10 mM dithiothreitol (DTT),
1 mM each of dNTPs (all from Boehringer Mannheim) and 30 U
RNasin (Promega) in diethylpyro-carbonate (DEPC)-treated water.
To the positive RT reactions, 50U RT was added, and to negative
RT reactions, an equal volume of DEPC-treated water was added.
A series of primers for CXCR1 (NM_000634 50-TCC TCA TCT TCC
TGC TTT GC-30 862:881, 5-0GTA GGA GGT AAC ACG ATG ACG-30
1136:1116), CXCR2 (NM_001557 50-TCC TCA TCT TCC TGC TCT
GC-30 1178:1197, 50-AGT GTG CCC TGA AGA AGA GC-30
1476:1457), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, NM_002046 50-AGA ACA TCA TCC CTG CCT C-30
686:704, 50-GCC AAA TTC GTT GTC ATA CC-30 1032:1013) were
used and PCR was performed using a Perkin-Elmer Thermocycler
(Perkin-Elmer, Foster City, California). Typical reactions were car-
ried out with 1 mL of cDNA template in a total volume of 50 mL
containing PCR buffer (45 mM Tris pH 8.8, 11 mM (NH4)2SO4,
4.5 mM MgCl2, 200 mM dNTP, 110 mg per mL bovine serum albumin
(BSA), 6.7 mM b-mercaptoethanol and 4.4 mM EDTA, pH 8.8) and
10 pmol each of forward and reverse primers. DNA was denatured
at 941C for 5 min and held at the primer annealing temperature
during the addition of 1 IU of Taq polymerase (Promega, Madison,
Wisconsin), followed by an extension step at 721C for 30 s. For
CXCR1 and CXCR2 primers the following cycle profile was used:
951C for 1 min, 581C for 45 s, 721C for 1 min for 35 cycles, with a
final extension step at 721C for 7 min. For GAPDH, amplification
was performed for 25 cycles with a profile of 951C for 1 min, 601C
for 30 s, 721C for 30 s, with final extension of 721C for 7 min. The
PCR products were loaded on a 2% agarose gel containing 15 mg
per mL ethidium bromide and gels were run at 150 V for 2 h. The
resulting bands were visualized on a UV transilluminator and im-
ages captured using a gel documentation system. The results were
examined for models derived from three cases of psoriasis and
three controls.
Statistical analysis Data were analyzed using Student’s t test and
expressed as means  SD. Statistical significance was assumed
for po0.05.
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